الفهرس 
Introduction
Incidence of Pancreatic CancerOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
This retrospective study is done for patients presented to our clinical oncology unit in Assuit University Hospital during the period from 2009 to 2013. This study is done on patients with pathologically/cytologically proved cancer pancreas 38 patients, 20 males and 18 females were included in the study, the median age was 53.8 yrs ranging from 36-80 yrs. Most of them had adenocarcinoma of the pancreas. The main presenting symptoms were abdominal pain in 81.57% of the patients and jaundice in 73.68% of the patients The type of biopsy in the study was mainly by excisional biopsy in 34.21% of the patients. As regard site of the tumor it was mainly in the head of the pancreas in 76.3% of the patients followed by body of pancreas in 10.5% of the patients 25 patients were irresectable at presentation while 13 patients were resectable of whom 11 patients underwent radical whipples operation. Palliative surgery is done for only 2 patients The liver was the main site of metastasis in 19 patients(50%).As regard complications the main complications were nausea in 63.15% of the patients, vomiting in 68.42% of the patients, abdominal pain in 73.68% of the patients, diarrhea in 63.15% of the patients and hepatic toxicity in 52.63% of the patients.
Metastatic (stageVI) disease was the most common stage at time of presentation in 22 patients followed by localized disease in 10 patients followed by locally advanced disease in 6 patients.
As regard response to different treatment modalities there is PD in 44.73% of the patients, SD in 15.78% of the patients, PR in 13.15% of the patients and CR in 10.5% of the patients.
The mean value of progression free survival was 3.69 months with median value of 3 months.
The mean value of OS was 7.95 months with median value of 6 months.
Age, sex, PS, stage of the tumor were significantly affect the response and OS while smoking, site of the tumor, and CA19.9 show no significance All patients tolerate the treatment protocols and neither associated with life threatening events nor grade 3 or grade 4 toxicity.